This page was automatically translated and accurateness of translation is not guaranteed. Please refer to the English version for a source text.

Measuring Atomoxetine and Aroxybutynin In Patients With OSA

Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of Atomoxetine/Aroxybutynin (AD109) to Atomoxetine Alone or Placebo in Obstructive Sleep Apnea

Szponzorok

Vezető szponzor: Apnimed

Forrás Apnimed
Rövid összefoglaló

MARIPOSA is a randomized, double blind, placebo-controlled, parallel-arm 1-month study of AD109 in participants with OSA. Enrolled participants will be randomized to one of 5 parallel treatment arms.

Részletes leírás

MARIPOSA is a randomized, double blind, placebo-controlled, parallel-arm 1-month study in participants with OSA. A screening visit and polysomnograms (PSGs) will be conducted to establish that each participant meets study enrollment criteria. The screening PSGs will serve as the baseline for the PSGs conducted during the 3rd and 4th weeks of drug treatment. Enrolled participants will be randomized to one of 5 parallel treatment arms. The first week of dosing will be with a lower dose run-in of AD109 (or corresponding single-drug component or placebo), followed by the full dose taken in weeks 2-4. One combination tablet is taken each night immediately before lights out. A total of approximately 260 participants will be enrolled.

Átfogó állapot Not yet recruiting
Kezdő dátum 2021-09-30
teljesítési dátum 2022-04-01
Elsődleges befejezés dátuma 2022-04-01
Fázis Phase 2
Tanulmány típusa Interventional
Elsődleges eredmény
Intézkedés Időkeret
Change in AHI (4% definition) 1 month
Másodlagos eredmény
Intézkedés Időkeret
Change in AHI (4% definition) 1 month
Change in AHI (4% definition) 1 month
Change in HB 1 month
Beiratkozás 260
Feltétel
Közbelépés

Beavatkozás típusa: Drug

Beavatkozás neve: AD109 (atomoxetine/aroxybutynin)

Leírás: Matching (blinded) formulated AD109 oral tablet administered before sleep

Beavatkozás típusa: Drug

Beavatkozás neve: Atomoxetine Hydrochloride

Leírás: Matching (blinded) formulated atomoxetine oral tablet administered before sleep

Karcsoport címke: Atomoxetine

Beavatkozás típusa: Drug

Beavatkozás neve: Placebo

Leírás: Matching (blinded) formulated placebo oral tablet administered before sleep

Karcsoport címke: Placebo

Jogosultság

Kritériumok:

Inclusion Criteria: - Between 18 to 65 years of age for men and 75 for women, inclusive - AHI between 10 to 45 with <25% events central or mixed apneas - BMI between 18.5 and 38 kg/m2 Exclusion Criteria: - Current clinically significant sleep disorder other than OSA - Clinically significant craniofacial malformation or grade ≥3 tonsillar hypertrophy. - Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 drugs for control (combination drugs count as 1 drug). - Clinically significant neurological disorder, including epilepsy/convulsions. - History of clinically significant urinary retention, gastric retention or other severe decreased gastrointestinal motility condition - Severe or frequent gastroesophageal reflux or constipation - Participants with a history of using devices for OSA treatment, including CPAP, oral or nasal devices, or positional devices, may enroll as long as the devices have not been used for at least 2 weeks prior to first PSG and are not used during participation in the study

Nem:

All

Minimális életkor:

18 Years

Maximális életkor:

75 Years

Egészséges önkéntesek:

No

Általános kapcsolat A kapcsolatfelvételi adatok csak akkor jelennek meg, ha a vizsgálat alanyokat toboroz.
Ellenőrzés dátuma

2021-06-01

Felelős fél

típus: Sponsor

Kiterjesztett hozzáféréssel rendelkezik No
Állapot Tallózás
Fegyverek száma 5
Kar Csoport

Címke: AD109 Dose 1

típus: Experimental

Leírás: AD109 Dose 1

Címke: AD109 Dose 2

típus: Experimental

Leírás: AD109 Dose 2

Címke: AD109 Dose 3

típus: Experimental

Leírás: AD109 Dose 3

Címke: Atomoxetine

típus: Active Comparator

Leírás: Atomoxetine

Címke: Placebo

típus: Placebo Comparator

Leírás: Placebo

Betűszó MARIPOSA
Betegadatok No
Tanulmányterv információ

Kiosztás: Randomized

Beavatkozási modell: Parallel Assignment

Elsődleges cél: Treatment

Maszkolás: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

analytics
3
Iratkozz fel